Skip to Main Content

Author Details

Michael S Anglesio
University of British Columbia
2004
96
44
PMIDPaper TitleJournal TitlePublished Year
37874327Cell State of Origin Impacts Development of Distinct Endometriosis-Related Ovarian Carcinoma Histotypes.Cancer Res2024
37874327Cell State of Origin Impacts Development of Distinct Endometriosis-Related Ovarian Carcinoma Histotypes.Cancer Res2024
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36624343Single-cell transcriptomic analysis of endometriosis.Nat Genet2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
37544766Neuroproliferative dyspareunia in endometriosis and vestibulodynia.Sex Med Rev2023
36977195KRAS mutations and endometriosis burden of disease.J Pathol Clin Res2023
37544766Neuroproliferative dyspareunia in endometriosis and vestibulodynia.Sex Med Rev2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36977195KRAS mutations and endometriosis burden of disease.J Pathol Clin Res2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36624343Single-cell transcriptomic analysis of endometriosis.Nat Genet2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
34596362Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.J Pathol Clin Res2022
35715244Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes.Fertil Steril2022
36299398Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?Gynecol Oncol Rep2022
36031730The proteome of clear cell ovarian carcinoma.J Pathol2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
35931468Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.Gynecol Oncol2022
33770057Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma.Int J Gynecol Pathol2022
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
34596362Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.J Pathol Clin Res2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
35715244Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes.Fertil Steril2022
35931468Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.Gynecol Oncol2022
36031730The proteome of clear cell ovarian carcinoma.J Pathol2022
36299398Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?Gynecol Oncol Rep2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
33770057Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma.Int J Gynecol Pathol2022
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
32646752Pathogenesis of bowel endometriosis.Best Pract Res Clin Obstet Gynaecol2021
33469880Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.Reprod Sci2021
33660008Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer.J Cancer Res Clin Oncol2021
32646752Pathogenesis of bowel endometriosis.Best Pract Res Clin Obstet Gynaecol2021
33660008Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer.J Cancer Res Clin Oncol2021
33469880Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.Reprod Sci2021
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
31897818Histotype-specific analysis of acid ceramidase expression in ovarian cancer.Virchows Arch2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
32641237Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.Gynecol Oncol2020
33352957Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer.Cancers (Basel)2020
32737030Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.Clin Cancer Res2020
  • 1 - 50 of 192

Recommended Authors

Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2018
Number of shared co-authors 6
David N Brown
Memorial Sloan Kettering Cancer Center
Career Start Year 2018
Number of shared co-authors 4
Pier Selenica
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 10
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2014
Number of shared co-authors 7
Cathleen Matrai
Weill Cornell Medical Center
Career Start Year 2013
Number of shared co-authors 1
Yukie Bean
Oregon Health & Science University
Career Start Year 2013
Number of shared co-authors 78
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 12
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 17
Myriam Kossai
INSERM, Universite Clermont Auvergne
Career Start Year 2008
Number of shared co-authors 3
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 5
Yingmei Wang
Tianjin Medical University General Hospital
Career Start Year 2007
Number of shared co-authors 0
Divya Gupta
Emory University School of Medicine
Career Start Year 2006
Number of shared co-authors 2
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 3
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 23
Jennifer B Permuth
Moffitt Cancer Center
Career Start Year 2004
Number of shared co-authors 81
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 12
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 0
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 4
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2002
Number of shared co-authors 2
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 18
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 3
Susan C Modesitt
University of Virginia, Emily Couric Clinical Cancer Center
Career Start Year 1998
Number of shared co-authors 5
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 6
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 57
Paulette Mhawech-Fauceglia
University of Southern California
Career Start Year 1995
Number of shared co-authors 11
Denise C Connolly
Fox Chase Cancer Center
Career Start Year 1993
Number of shared co-authors 8
Ernst Lengyel
University of Chicago
Career Start Year 1993
Number of shared co-authors 33
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 39
Lora H Ellenson
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 8
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 4

Collaborators

David G Huntsman
University of British Columbia
Co-authored papers 60
Cyril B Gilks
University of British Columbia
Co-authored papers 38
Martin K??bel
University of Calgary
Co-authored papers 29
Janine Senz
University of British Columbia
Co-authored papers 27
Stefan Kommoss
Eberhard Karls University Tubingen
Co-authored papers 26
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 24
Anna DeFazio
Westmead Hospital
Co-authored papers 23
Aline Talhouk
The University of British Columbia
Co-authored papers 20
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 19
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 17
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 17
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 15
Linda E Kelemen
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 14
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 14
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 14
Steve E Kalloger
University of British Columbia
Co-authored papers 13
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 13
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 13
Tayyebeh M Nazeran
University of British Columbia
Co-authored papers 13
Mercedes Jimenez-Linan
University of Cambridge
Co-authored papers 12
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 12
Jennifer Alsop
University of Cambridge
Co-authored papers 12
Samuel Leung
University of British Columbia
Co-authored papers 11
Naveena Singh
Barts Health NHS Trust
Co-authored papers 11
Sohrab P Shah
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Ian G Campbell
Co-authored papers 11
Stacey J Winham
Mayo Clinic
Co-authored papers 11
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 11
Derek S Chiu
University of British Columbia, and Vancouver General Hospital
Co-authored papers 11
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 11
Release 1.2